Pharma AI

Field Force Effectiveness & Sales Force Sizing in Pharma

By Multiplier AI Team · Published August 14, 2026

Most field force effectiveness programmes measure the wrong thing, and most sales force sizing exercises answer a question that stopped being the right one somewhere around 2023. Both problems have the same root cause: the industry built its measurement and sizing logic in an era when a representative who made more calls reached more physicians, and reaching more physicians produced more prescriptions. That chain has been breaking for fifteen years and it broke faster in the last three.

Veeva's Pulse data, drawn from hundreds of millions of annual interactions, found healthcare professional access falling from 60% to 45% in eighteen months. Half of the professionals who remain accessible restrict their engagement to three companies or fewer, and in several specialties close to a third will see only one. Meanwhile roughly 80% of approved promotional content is rarely or never used in the field, and around 90% of the interactions that do happen last under two minutes.

A sizing model built on call capacity, in that environment, will confidently recommend a field force optimised for a market that no longer exists. This guide covers what to measure instead, the six sizing methods and when each is defensible, what changes in India specifically, and how to answer the two questions commercial leaders are now asking artificial intelligence assistants about territory alignment and field force agents.

What field force effectiveness actually measures

Field force effectiveness is the relationship between what a field organisation costs, what it does, and what changes as a result. Most programmes measure only the middle term. A complete framework needs four levels: inputs (people and cost), activities (calls, coverage, frequency), quality (what happened inside the interaction), and outcomes (prescriber behaviour change). Activity without quality tells you the plan was followed. Quality without outcomes tells you the interactions were good. Only the full chain tells you the field force is working.
The reason this matters more now than it did is that the correlation between the second and fourth levels has weakened. When most physicians would see most representatives, call volume was a reasonable proxy for reach, and reach was a reasonable proxy for influence. Neither holds when a physician sees three companies out of the twenty calling, and gives each under two minutes.

Level	Representative metrics	What it tells you	Where it misleads
Input	Field headcount, fully loaded cost per representative, cost per call, share of revenue spent on sales and promotion	What the organisation costs and how that compares to peers	Benchmarks invite copying a competitor's structure without their portfolio or access position
Activity	Calls per day, coverage of target list, frequency by segment, call plan adherence, sample and input distribution	Whether the plan was executed	It is the easiest level to measure and the easiest to game, so it dominates dashboards regardless of usefulness
Quality	Duration, content shared, message recall, next-step secured, physician-initiated follow-up	Whether the interaction was worth the physician's time	Rarely captured at all. Where it is, it usually depends on the representative's own reporting
Outcome	Prescriber behaviour change against a matched control, new patient starts, formulary and stocking movement, share of voice converted to share of mind	Whether the field force changed anything	Attribution is genuinely hard, and in markets without prescriber-level data it must be modelled rather than measured
Enablement	CRM adoption and reporting latency, content utilisation, time spent on administration versus selling	Whether the system supporting the field force is helping or taxing it	Treated as an IT metric rather than a commercial one, which is why it is usually the last thing fixed

A practical test for any effectiveness dashboard: count how many of its metrics sit at the activity level. If it is more than half, the dashboard is a compliance instrument rather than a management one. It will tell you reliably which representatives are following the plan, and almost nothing about whether the plan deserves following.

The number that changed the sizing question

Healthcare professional access fell from 60% to 45% in eighteen months according to Veeva Pulse, and among those still accessible, half restrict engagement to three companies or fewer while close to 30% in specialties including internal medicine, oncology, psychiatry and urology will see only one. This inverts the sizing problem. The constraint is no longer how many calls a field force can make; it is how many physicians will accept a call at all, and how many companies they will accept it from. Capacity-based sizing models are answering a supply question in a market that has become demand-constrained.
This is not a sudden change so much as a long trend that accelerated. ZS Associates began tracking physician access restrictions in 2008, when 23% of physicians were access-restricted. By 2014 that figure was 49%, and by 2015 it was 53%. ZS estimated at the time that the industry was spending roughly a billion dollars a year on calls that could never have succeeded — itself an improvement on nearly three billion in 2008, which indicates the industry had already begun adjusting.

What the access data shows	Figure and source	Consequence for sizing
Overall HCP access	Fell from 60% to 45% over eighteen months (Veeva Pulse, May 2024)	Any model that assumes a stable callable universe will oversize. Re-derive the reachable universe before applying any method
Concentration among accessible HCPs	50% of accessible HCPs restrict to three companies or fewer (Veeva Pulse, May 2024)	Being fourth in line is worth close to zero. Share of voice logic breaks down — you are either in the set or you are not
Specialty exclusivity	Close to 30% in internal medicine, oncology, psychiatry and urology see only one company (Veeva Pulse, May 2024)	In these specialties the question is not frequency but whether you can earn the single slot. That is a capability investment, not a headcount one
Long-run access trend	Physicians access-restricted: 23% in 2008, 49% in 2014, 53% in 2015 (ZS AccessMonitor)	The direction has been consistent for nearly two decades. Plan for continued decline rather than reversion
Cost of unreachable calls	~$1bn annually in 2015, down from ~$3bn in 2008 (ZS estimate)	Waste is concentrated in calling on physicians who were never going to engage. Targeting accuracy beats capacity
Interaction length	Around 90% of interactions last under two minutes	Sizing for detail time is unrealistic. Size for the message that fits, and move depth to other channels
Content actually used	Roughly 80% of approved content is rarely or never used; field teams share materials in fewer than half of interactions (Veeva Pulse, May 2025)	Adding representatives multiplies an execution problem. Fix content utilisation before adding capacity

There is a constructive finding buried in the same research. Veeva reported that content-driven engagements double treatment starts, and that connected engagement models reduce time between meetings by up to 25% and increase the likelihood of a follow-up conversation by up to 20%. In other words the productivity available from making existing interactions better is substantial, and it is available without adding a single representative. We covered the execution side of this in scaling personalized physician content.

How to size a pharma sales force: six methods compared

Six methods are used in practice: same as last year, cost of sales, share of voice, workload build-up, affordable coverage, and sales response modelling. The first three are diagnostics rather than answers — they tell you whether your current size is unusual, not whether it is right. Workload build-up is the practical default for most organisations. Affordable coverage adds financial rigour. Sales response modelling is the most defensible to a chief financial officer and the most demanding of data. Run at least two and reconcile the difference; a single method produces a number, two methods produce an argument.

Method	How it works	Strengths	When it fails
Same as last year	Carry forward the current headcount	Fast and free. Occasionally correct	Ignores access changes, portfolio changes and competitive movement. Entrenches historical error
Cost of sales	Set field investment as a fixed share of revenue, for example 6%	Simple, finance-legible, easy to govern	Reverses causality — it treats sales as driving investment rather than investment driving sales
Share of voice	Size against competitor field forces to hold relative presence	Externally focused and a genuinely useful diagnostic	Breaks down when access is concentrated. Matching a competitor's headcount does not buy you their access
Workload build-up	Count the target universe, set coverage and frequency by segment, divide by realistic call capacity	Practical, produces segmentation and territory guidance, supports scenario comparison	Treats all covered customers as equally worth covering, and produces no financial or ROI output
Affordable coverage	Derive sustainable size from the sales forecast, profitability hurdles, sales economics and carryover in vacant territories	Combines workload logic with financial discipline	Mathematically demanding, and it requires a sales forecast as an input rather than producing one
Sales response modelling	Model revenue at different field sizes statistically, and optimise where marginal revenue equals marginal cost	The most defensible to finance, and supports genuine scenario analysis	Needs granular reliable activity and outcome data and real analytical capability. Rarely feasible in markets without prescriber-level data

Two practical notes. First, workload build-up is only as good as the universe it starts from — and with access at 45%, the universe should be the reachable prescriber set rather than the registered one. Building workload from a target list that includes physicians who will never grant a call produces a precisely calculated wrong answer. Second, carryover is the variable most often guessed and most consequential: if a vacant territory retains 70% of its revenue for two quarters, the case for filling it quickly is very different from a territory that retains 30%.

AI tools for territory alignment for a 500-rep field force

At 500 representatives, territory alignment is beyond manual optimisation and mature commercial software exists for it — Axtria, ZS, IQVIA and the alignment modules inside major CRM suites all handle the core optimisation problem well. The genuinely new capability is not the first alignment but the rework cycle: agentic AI is now being applied to continuous realignment, workload rebalancing and call plan adjustment as territories drift. Buy proven optimisation for the alignment itself, and treat AI as the layer that keeps it current between formal exercises.
The distinction matters commercially. A 500-representative alignment is a constrained optimisation problem with well-understood mathematics — balance workload and potential, respect geography and travel time, minimise disruption to existing relationships, honour reporting structures. That problem was solved competently a decade ago. What was never solved is the fact that alignments decay from the day they are published, and that most organisations tolerate eighteen months of accumulating imbalance because a realignment is disruptive and politically expensive.

Capability	What to look for at 500 reps	Mature or emerging?	How to evaluate it
Core alignment optimisation	Multi-objective optimisation across workload, potential, travel time and disruption, with scenario comparison	Mature — buy, do not build	Run your current alignment through it and see whether it reproduces or improves on decisions you already trust
Disruption modelling	Explicit constraint on how many relationships are broken, not just an efficiency score	Mature	Ask for the disruption count alongside every scenario. A 4% efficiency gain that breaks 30% of relationships is a bad trade
Continuous rebalancing	Detection of drift between formal alignments, with proposed incremental corrections	Emerging, and the strongest current AI use case	Ask what triggers a recommendation and whether a human approves each change
Call plan optimisation	Segment-level frequency recommendations that account for actual access, not just potential	Emerging	Confirm it consumes access and engagement data rather than only potential and historical call history
Field input and override	A route for representatives to correct territory assumptions and record why	Often missing entirely	This is the difference between an alignment the field executes and one it works around. Insist on it
Change management support	Communication artefacts, transition plans and explanation of why each territory changed	Underserved by software, and it is where alignments actually fail	Ask to see what the representative receives, not what the analyst sees

One caution specific to large field forces. The temptation at 500 representatives is to optimise for aggregate efficiency, because a 3% improvement is worth a great deal at that scale. But alignment quality is experienced individually — a representative who loses their three best accounts experiences a 3% aggregate gain as a personal loss, and the resulting attrition and disengagement routinely exceeds the modelled benefit. Constrain for disruption explicitly, and treat the field's acceptance of the alignment as a success criterion rather than a communication task.

Do we need agents or copilots for our field force?

Start with copilots, and scope agents narrowly. A copilot assists a representative who remains in control — drafting the call report, summarising a physician's history before a visit, answering a product question. An agent acts on its own and reports afterwards. In regulated field work the value available today is overwhelmingly in the copilot category, and specifically in removing administrative load: voice-to-text call reporting alone recovers time that no amount of territory optimisation will. Agents are justified where the task is reversible, auditable and low-stakes — flagging drift, preparing drafts, queueing follow-ups — not where they contact a physician unsupervised.
The category moved from roadmap to production recently enough that many buyers still think of it as future tense. Veeva made AI agents available inside Vault CRM on 3 December 2025, including a Voice Agent and a Pre-call Agent, alongside content agents in PromoMats. The practical question is therefore no longer whether these exist but which of them earn their place in a field organisation, and in what order.

Use case	Copilot or agent?	Value available today	What to check before deploying
Voice-to-text call reporting	Copilot	The highest-return single deployment. Reporting is the most resented administrative task and the one most often done late, badly or in a car park at the end of the day	Accuracy on local accents and product names; whether the transcript is editable before submission; where the audio is stored
Pre-call preparation	Copilot	High. Summarising the last three interactions, open commitments and current formulary status is work representatives frequently skip under time pressure	That it reads from the actual customer record rather than generating plausible-sounding history
Product and medical question answering	Copilot	High, with governance. Reduces off-label risk if it answers only from approved content	That responses are restricted to the approved content library, and that unanswerable questions route to medical affairs
Territory drift detection	Agent	Moderate to high, and low risk because the output is a recommendation to a manager	Who approves the change, and whether the reasoning is inspectable
Suggested next action	Agent	Moderate. Valuable when it consumes real access and engagement signals, weak when it restates the call plan	Whether representatives can reject a suggestion and record why — and whether anyone reads those rejections
Autonomous HCP contact	Agent	Low today, and high risk in a regulated context	Consent state checked at send, content approval binding, and a complete audit trail. If any is missing, do not deploy
Administrative workflow — expenses, samples, scheduling	Agent	Underrated. Often the fastest measurable time recovery in the whole list	Integration with the systems of record, and a clean exception path when the agent cannot complete the task

The sequencing advice is straightforward. Deploy copilots that remove administration first, because the benefit is immediate, the risk is low and the field will advocate for them. Add advisory agents next, where a human approves the output. Reserve autonomous action for tasks that do not touch a physician. A field organisation that has been given back an hour a day will accept the next thing you deploy; one that has been given a suggestion engine it did not ask for will not.

CRM adoption: the metric that invalidates all the others

Every field force effectiveness number is derived from what representatives report, which makes reporting behaviour the foundation of the entire measurement system. If calls are logged days late, in batches, from memory, or reconstructed to match the plan, then coverage, frequency, call quality and every downstream analysis are describing the reporting process rather than the commercial reality. Measure reporting latency and completeness before you trust any effectiveness metric, and treat a low adoption figure as a data integrity emergency rather than a training issue.
The diagnostic is simple and rarely run. Take the distribution of the gap between when a call happened and when it was logged. In a healthy organisation most calls are logged the same day and the distribution has a short tail. In an unhealthy one there is a spike at the end of each week or month, which is the signature of reconstruction rather than recording — and reconstructed calls are, by definition, reported against the plan rather than against what happened.

Adoption signal	What healthy looks like	What it means when it is wrong
Reporting latency	Most calls logged the same day, short tail	End-of-period spikes indicate reconstruction. Coverage and frequency figures become unreliable
Completeness of qualitative fields	Call outcome, content shared and next step populated on the large majority of calls	Blank qualitative fields mean the system is being used for compliance, not for management
Variance between representatives	A reasonable spread around a clear norm	Bimodal distributions usually indicate two different reporting cultures under different managers, not two levels of performance
Content utilisation	Approved materials shared in a meaningful share of calls — against an industry position where roughly 80% of content is rarely or never used	Very low utilisation means content is not fit for the interaction, not that representatives are non-compliant
Administrative time share	Administration a modest and falling share of the working day	A high share is a direct capacity loss and the strongest business case for copilots
Override and rejection logging	Representatives can reject a suggested action and record a reason, and those reasons are reviewed	If rejections are impossible, the field routes around the system silently and you lose the signal entirely

There is a management point underneath the technical one. Reporting quality is usually a function of whether the field believes the data is used for their benefit or against them. Where the CRM is experienced primarily as surveillance, reporting degrades toward the minimum that avoids sanction. Where it visibly returns something — better pre-call context, fewer wasted journeys, faster expense settlement — it improves without enforcement. That is the strongest practical argument for deploying administrative copilots before analytical ones.

What changes in India and comparable markets

Three things change. The field force is larger relative to revenue and remains the primary channel rather than one of several, so sizing decisions are proportionally more consequential. There is no prescriber-level prescription data, so sales response modelling is generally unavailable and outcome measurement must be modelled from territory-level movement. And market growth has turned price and mix led — the Indian pharmaceutical market grew 10.3% in value against 0.8% in volume in April 2026 — which removes the traditional justification for adding representatives to capture volume growth.
That last point deserves emphasis because it changes the direction of the sizing conversation. When volume is growing, a larger field force can be justified by reaching more prescribers. When value growth comes from price and mix while volume is flat, additional revenue comes from moving existing prescribers to different products — which is a targeting, message and capability problem rather than a coverage problem. Adding representatives to a flat-volume market usually adds cost to the same interactions.

Factor	Position in India	Implication for sizing and effectiveness
Field force scale	Industry estimates place medical representative employment above six lakh nationally, with large companies running field forces in the region of 12,000 each	Small percentage changes in productivity are worth more than they are in smaller markets. Effectiveness work outperforms sizing work
Cost structure	Sales, promotion and distribution around 8% of revenue; top companies reported to allocate close to 20% of total expenditure to recruiting and training representatives	Attrition is a direct and large cost. Retention is an effectiveness lever, not an HR side issue
Market growth mix	10.3% value growth against 0.8% volume growth, April 2026 (Pharmarack Pharmatrac)	Coverage expansion is hard to justify. Targeting accuracy and message relevance carry the return
Prescription data	No prescriber-level prescription data; secondary sales available at stockist and territory level	Sales response modelling is generally not feasible. Use workload build-up plus a modelled outcome proxy with a matched control
Channel position	The representative remains the primary channel by influence, with WhatsApp as the working digital channel	Digital does not substitute for the call here so much as extend it. Size the field with the digital layer as an amplifier, not a replacement
Doctor data quality	Discrepancy rates around 57% in pharma CRM doctor records in our audits	Territory potential calculated on a duplicated master is wrong at source. Clean the master before any alignment exercise
Geography	Multi-location practice is normal — a government posting, a private clinic and a visiting arrangement	Travel time models built on one address per doctor understate workload substantially in tier-2 and tier-3 territories

The doctor data point is the one most often skipped and most damaging. Territory potential, workload build-up and alignment all begin from a customer master. If that master carries a high duplication rate, the resulting territories are balanced against a fictional universe — and the imbalance appears later as unexplained variance in representative performance that no amount of coaching resolves. We set out how to approach this in doctor data validation and enrichment.

A 45-day field force effectiveness diagnostic

This sequence is designed to establish whether your problem is size, structure, execution or measurement — before anyone commissions a sizing study. In a majority of the engagements we see, the answer is not size.

Days 1–5: audit the customer master. Establish the duplication rate, the proportion of records with a current practice address, and how many practitioners hold multiple locations. Every subsequent calculation inherits this. If duplication is material, stop and fix it before proceeding — territory potential built on a duplicated master cannot be repaired downstream.
Days 6–10: measure reporting integrity, not reported activity. Pull the distribution of the gap between call occurrence and call logging. Look for end-of-period spikes. Measure completeness of qualitative fields. This determines how much weight any later metric can carry.
Days 11–17: derive the reachable universe. Segment your target list by actual access rather than by potential alone. How many of your targets have granted a call in the last two quarters? How many see three or fewer companies? The gap between the target list and the reachable list is usually the single largest finding in the diagnostic.
Days 18–22: measure the interaction, not the call. Sample interactions for duration, content shared, next step secured and physician-initiated follow-up. Compare high and low performing territories on these quality measures rather than on call counts, which typically differ far less than results do.
Days 23–28: quantify the administrative tax. Time-and-motion a representative sample: selling time, travel, administration, reporting, internal meetings. This produces both the copilot business case and a realistic call capacity figure for any sizing model.
Days 29–34: run two sizing methods, not one. Workload build-up against the reachable universe, plus either affordable coverage or sales response modelling depending on data availability. Reconcile the difference explicitly — the gap between the two is where the real assumptions live.
Days 35–40: test alignment health before considering realignment. Measure workload and potential imbalance across territories, and estimate relationship disruption for any proposed change. A realignment that improves balance by a few percent while breaking a third of relationships is usually value-destroying.
Days 41–45: sequence the interventions and price them. Rank by return and by speed: data cleansing, administrative copilots, content utilisation, call plan changes, alignment, and only then headcount. Headcount is the slowest, most expensive and least reversible lever, and it should be the last one pulled, not the first.

Treat the first and second steps as gating. A diagnostic run on a duplicated customer master or on reconstructed call data will produce confident conclusions that are wrong in ways nobody can later detect, and it will be used to justify a headcount decision that lasts for years.

Where Multiplier AI fits — and where it does not

Field force effectiveness is a broad discipline and we address one part of it. The boundaries are worth stating plainly.

Do not shortlist us if

You need a sales force sizing study. Response modelling, affordable coverage analysis and formal sizing are consulting disciplines served by Axtria, ZS, IQVIA and comparable firms. We do not do this work and we would not do it well.
You need territory alignment optimisation software. The optimisation problem is mature and well served. Buy a proven alignment tool rather than expecting an execution platform to solve it.
You need incentive compensation design. Plan design, quota setting and payout administration are a specialist category with established vendors. Poor incentive design will defeat any effectiveness programme, and it needs its own expertise.
Your field force runs on a system of record you are not willing to integrate with. Our value depends on connecting to the customer record. If that connection is out of scope, so are we.

Do shortlist us if

Your customer master is the reason your territories are unbalanced. The discrepancy rate we observe in pharma CRM doctor records is around 57%. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters, including the multi-location practice patterns that distort workload models.
Content utilisation is throttling your field force. Where roughly 80% of approved content goes unused, the constraint is production and relevance rather than representative behaviour. Our Hyper Personalized Content Platform addresses that directly.
You want measured field productivity improvement rather than a plan for it. Published outcomes from our Indian deployments include a minimum 120% increase in time spent in the doctor's cabin, a 37% increase in medical representative efficiency and a 35% increase in brand share of voice with doctor influencers.
Your effectiveness problem is execution rather than structure. If the diagnostic in section eight points at data, content and administrative load rather than at headcount, that is the work we do.

The mistakes that make field forces expensive

Sizing against the target universe rather than the reachable one. With access at 45%, a target list built on potential alone will oversize the field force and disguise the error as a coverage shortfall.
Treating activity metrics as effectiveness metrics. Calls per day measures compliance with a plan. It has become a weak predictor of outcome and a strong predictor of nothing else.
Running a sizing study on a duplicated customer master. Territory potential calculated from a master with high duplication produces imbalance that later looks like performance variance and gets managed as a people problem.
Adding headcount to fix an execution problem. If content is unused, reporting is reconstructed and administration consumes selling time, more representatives multiply the problem at proportional cost.
Optimising alignment for aggregate efficiency. A few percent of modelled gain is routinely erased by the attrition and disengagement that follow heavy relationship disruption. Constrain for disruption explicitly.
Deploying analytical AI before administrative AI. A field force that has been given back an hour a day will adopt what comes next. One given an unrequested suggestion engine will not.
Ignoring carryover in vacancy decisions. How much revenue a vacant territory retains, and for how long, changes the economics of both vacancy tolerance and field force size, and it is usually guessed.

Fix the interaction before you change the number

Field force sizing has an unusual property among commercial decisions: it is slow to implement, expensive to reverse, and highly visible. That combination makes it attractive as an answer, because it looks decisive. It is also why sizing exercises are often commissioned to resolve problems that sizing cannot address — content that does not get used, reporting that does not reflect reality, territories balanced against a customer master nobody has audited, and a target universe that includes thousands of physicians who will not grant a call to anyone.

The diagnostic sequence in this article is deliberately ordered so that headcount is the last lever considered rather than the first. Not because field forces never need resizing — they frequently do, particularly as access continues to fall and portfolios shift — but because the cheaper, faster and more reversible interventions almost always sit upstream of it. An organisation that recovers an hour a day per representative through better reporting tools, doubles content utilisation and cleans a duplicated customer master has changed its effective capacity substantially without changing its headcount at all.

Size the field force you need for the market that exists. Then spend most of your energy on what happens inside the interactions it makes.

Work with Multiplier AI

Multiplier AI improves field force productivity for pharma commercial teams in India and other emerging markets by fixing the two things that most often throttle it: the customer master and the content. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters, including the multi-location practice patterns that distort territory workload models, and our Hyper Personalized Content Platform builds and delivers personalised content across email, WhatsApp and social so that approved material actually reaches the interaction. Published outcomes from Indian deployments include a minimum 120% increase in time spent in the doctor's cabin, a 37% increase in medical representative efficiency and a 35% increase in brand share of voice with doctor influencers. See our pharma solutions page, review our case studies, or book a demo — and bring your reporting latency distribution. It usually tells us more in five minutes than a quarter of dashboards.

Frequently Asked Questions For Field Force Effectiveness & Sales Force Sizing in Pharma

It is the relationship between what a field organisation costs, what it does and what changes as a result. A complete framework measures five things: inputs such as headcount and cost, activities such as calls and coverage, the quality of each interaction, the outcomes in prescriber behaviour, and the enablement layer of systems and content that supports the field. Most programmes measure activity thoroughly and the other four barely at all.

Six methods are used: same as last year, cost of sales, share of voice, workload build-up, affordable coverage and sales response modelling. Workload build-up is the practical default — count the reachable target universe, set coverage and frequency by segment, and divide by realistic call capacity after subtracting travel and administration. Run a second method alongside it and reconcile the difference, because the gap between two methods is where the real assumptions become visible.

Sizing determines how many representatives you need. Alignment determines which customers and geography each one covers. They are sequential — alignment on the wrong size produces balanced territories that are collectively too large or too small — but they are frequently conflated, and organisations sometimes attempt to fix a sizing problem through realignment, which redistributes the shortfall rather than resolving it.

Beyond the standard activity set of calls, coverage and frequency, the metrics that actually differentiate performance are: reachable universe penetration, interaction quality measures such as content shared and next step secured, physician-initiated follow-up, CRM reporting latency, content utilisation rate, administrative share of the working day, and outcome movement against a matched control group of similar prescribers.

Substantially. Veeva Pulse recorded access falling from 60% to 45% in eighteen months, with half of accessible professionals restricting engagement to three companies or fewer and close to 30% in several specialties seeing only one. This means the callable universe is far smaller than the target universe, so capacity-based sizing overstates the requirement. Recalculate the reachable universe before applying any sizing method.

Start with copilots. A copilot assists a representative who stays in control — voice-to-text call reporting, pre-call summaries, approved-content question answering — and delivers immediate value at low regulatory risk. Agents that act autonomously are appropriate for reversible, auditable tasks such as territory drift detection and administrative workflow, and are not yet appropriate for unsupervised contact with a physician. Deploy administrative copilots first; adoption of everything else improves once the field has gained time.

Rather than adopting a benchmark, derive it. Time-and-motion a representative sample to establish selling time after travel, administration and internal meetings, then apply your own access rates by segment. Benchmarks from other companies embed their geography, portfolio and access position, and importing them is one of the more common ways a sizing model acquires an untested assumption.

Combine territory-level secondary sales movement, interaction quality measures, structured field-reported prescriber intent and content engagement depth, then compare against a matched control set of similar prescribers with different exposure. Report the result as a confidence range with the control construction documented. This is defensible; presenting the same numbers as attribution is not.